Wegener Polyangiitis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wegener Polyangiitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Wegener Polyangiitis - Pipeline Review, H2 2015', provides an overview of the Wegener Polyangiitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wegener Polyangiitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener Polyangiitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wegener Polyangiitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Wegener Polyangiitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Wegener Polyangiitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wegener Polyangiitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wegener Polyangiitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wegener Polyangiitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Wegener Polyangiitis Overview 7
Therapeutics Development 8
Pipeline Products for Wegener Polyangiitis - Overview 8
Wegener Polyangiitis - Therapeutics under Development by Companies 9
Wegener Polyangiitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Wegener Polyangiitis - Products under Development by Companies 14
Wegener Polyangiitis - Companies Involved in Therapeutics Development 15
Bionovis SA 15
Bristol-Myers Squibb Company 16
ChemoCentryx, Inc. 17
Coherus BioSciences, Inc. 18
Epirus Biopharmaceuticals, Inc. 19
Genor BioPharma Co., Ltd. 20
GlaxoSmithKline Plc 21
Hospira, Inc. 22
Panacea Biotec Limited 23
Sandoz International GmbH 24
The International Biotechnology Center (IBC) Generium 25
Wegener Polyangiitis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
abatacept - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
belimumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CCX-168 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rituximab biosimilar - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
rituximab biosimilar - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rituximab biosimilar - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
rituximab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rituximab biosimilar - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rituximab biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
rituximab biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
rituximab biosimilar - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
rituximab biosimilar - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Wegener Polyangiitis - Recent Pipeline Updates 53
Wegener Polyangiitis - Dormant Projects 62
Wegener Polyangiitis - Discontinued Products 63
Wegener Polyangiitis - Product Development Milestones 64
Featured News & Press Releases 64
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for Wegener Polyangiitis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Comparative Analysis by Unknown Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Wegener Polyangiitis - Pipeline by Bionovis SA, H2 2015 15
Wegener Polyangiitis - Pipeline by Bristol-Myers Squibb Company, H2 2015 16
Wegener Polyangiitis - Pipeline by ChemoCentryx, Inc., H2 2015 17
Wegener Polyangiitis - Pipeline by Coherus BioSciences, Inc., H2 2015 18
Wegener Polyangiitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 19
Wegener Polyangiitis - Pipeline by Genor BioPharma Co., Ltd., H2 2015 20
Wegener Polyangiitis - Pipeline by GlaxoSmithKline Plc, H2 2015 21
Wegener Polyangiitis - Pipeline by Hospira, Inc., H2 2015 22
Wegener Polyangiitis - Pipeline by Panacea Biotec Limited, H2 2015 23
Wegener Polyangiitis - Pipeline by Sandoz International GmbH, H2 2015 24
Wegener Polyangiitis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 25
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Wegener Polyangiitis Therapeutics - Recent Pipeline Updates, H2 2015 53
Wegener Polyangiitis - Dormant Projects, H2 2015 62
Wegener Polyangiitis - Discontinued Products, H2 2015 63